BioArctic Reports Record Revenue Growth on Leqembi Royalties

Event summary

  • BioArctic reports Q4 2025 net revenues of SEK 184.0M, up from SEK 101.2M, with SEK 127.0M from Leqembi royalties.
  • Leqembi Iqlik launched for weekly maintenance dosing in the US, with FDA priority review for subcutaneous initiation treatment expected by May 2026.
  • Company proposes SEK 2.00 dividend per share for 2025, with cash position doubling to SEK 2,190.4M.
  • BioArctic advances pipeline with new projects in Huntington's disease and Parkinson's, nominating candidate drugs for clinical studies.

The big picture

BioArctic's strong financial performance underscores the commercial success of Leqembi, now approved in over 50 markets. The company's strategic focus on expanding its pipeline and leveraging its BrainTransporter technology positions it to capitalize on growing demand for neurodegenerative disease treatments. However, regulatory delays in Europe and pricing pressures in key markets like Japan present challenges to sustained growth.

What we're watching

Regulatory Momentum
Whether FDA, EMA, and other global regulators will accelerate Leqembi approvals beyond current timelines.
Revenue Diversification
How BioArctic's new pipeline projects will contribute to long-term revenue growth beyond Leqembi royalties.
Geographic Expansion
The pace at which BioArctic and Eisai can expand Leqembi's market reach, particularly in Europe and emerging markets.